Debt - Additional Information (Details)
|
|
|
|
|
|
|
3 Months Ended |
9 Months Ended |
|
Nov. 02, 2020
USD ($)
$ / shares
shares
|
Oct. 27, 2020
USD ($)
$ / shares
shares
|
Sep. 08, 2020
USD ($)
Debtinstrument
$ / shares
shares
|
Apr. 30, 2020
USD ($)
|
Jan. 21, 2020
USD ($)
Debtinstrument
$ / shares
shares
|
Apr. 27, 2018
USD ($)
$ / shares
shares
|
Sep. 30, 2020
USD ($)
$ / shares
shares
|
Sep. 30, 2020
USD ($)
$ / shares
shares
|
Sep. 30, 2019
USD ($)
|
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
| Accretion of debt discounts and deferred financing costs |
|
|
|
|
|
|
|
$ 7,818,000
|
$ 243,000
|
| Financing transaction costs |
|
|
|
|
|
|
$ 685,000
|
$ 2,815,000
|
|
| Ordinary Shares |
|
|
|
|
|
|
|
|
|
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
| Number of warrants to purchase ordinary shares | shares |
|
|
|
|
|
19,890
|
19,890
|
19,890
|
|
| Loan and Security Agreement | Silicon Valley Bank (SVB) |
|
|
|
|
|
|
|
|
|
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
| Loan and security agreement entered date |
|
|
|
|
|
|
|
Apr. 27, 2018
|
|
| Funded amount under agreement |
|
|
|
|
|
$ 15,000,000
|
|
|
|
| Remaining borrowing facility available date |
|
|
|
|
|
Oct. 31, 2019
|
|
|
|
| Maximum amount available under agreement |
|
|
|
|
|
$ 30,000,000
|
|
|
|
| Non-utilization fee percentage of undrawn principal amount |
|
|
|
|
|
1.50%
|
|
|
|
| Frequency of amortization payments |
|
|
|
|
|
|
|
Monthly
|
|
| Date of first required payment of initial draw |
|
|
|
|
|
Nov. 01, 2019
|
|
|
|
| Minimum fixed interest rate per annum |
|
|
|
|
|
8.31%
|
|
|
|
| Final interest rate payment on outstanding principal |
|
|
|
|
|
4.20%
|
|
|
|
| Principal and interest payment, maturity date |
|
|
|
|
|
Mar. 01, 2022
|
|
|
|
| Final payment fee |
|
|
|
|
|
$ 630,000
|
|
|
|
| Prepayment fee in first year |
|
|
|
|
|
4.00%
|
|
|
|
| Prepayment fee in second year |
|
|
|
|
|
3.00%
|
|
|
|
| Prepayment fee thereafter |
|
|
|
|
|
2.00%
|
|
|
|
| Principal payment during the period |
|
|
|
|
|
$ 4,655,000
|
|
|
|
| Effective annual interest rate on outstanding debt |
|
|
|
|
|
|
12.51%
|
12.51%
|
|
| Interest expense |
|
|
|
|
|
|
|
$ 1,091,000
|
1,310,000
|
| Accretion of debt discounts and deferred financing costs |
|
|
|
|
|
|
|
$ 324,000
|
$ 243,000
|
| Loan and Security Agreement | Silicon Valley Bank (SVB) | Wall Street Journal Prime Rate |
|
|
|
|
|
|
|
|
|
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
| Basis spread on interest rate |
|
|
|
|
|
3.89%
|
|
|
|
| Loan and Security Agreement | Silicon Valley Bank (SVB) | Maximum |
|
|
|
|
|
|
|
|
|
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
| Maximum amount available under second draw |
|
|
|
|
|
$ 15,000,000
|
|
|
|
| Silicon Valley Bank and Life Sciences Fund II LLC |
|
|
|
|
|
|
|
|
|
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
| Percentage of purchase additional ordinary shares equal to term loan divided by applicable exercise price |
|
|
|
|
|
2.50%
|
|
|
|
| Silicon Valley Bank and Life Sciences Fund II LLC | Series B Convertible Preferred Shares |
|
|
|
|
|
|
|
|
|
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
| Number of warrants to purchase ordinary shares | shares |
|
|
|
|
|
19,890
|
19,890
|
19,890
|
|
| Warrants to purchase ordinary shares, exercise price | $ / shares |
|
|
|
|
|
$ 18.85
|
$ 18.85
|
$ 18.85
|
|
| 2025 Exchangeable Notes |
|
|
|
|
|
|
|
|
|
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
| Interest expense |
|
|
|
|
|
|
$ 860,000
|
$ 2,339,000
|
|
| Accretion of debt discounts and deferred financing costs |
|
|
|
|
|
|
2,062,000
|
$ 5,665,000
|
|
| Debt instrument, payment terms |
|
|
|
|
|
|
|
The Company will be required to pay the holder of the Exchangeable Notes the greater of three times the outstanding principal amount of such Exchangeable Note and the consideration that would be received by the holder of such Exchangeable Note in connection with such Fundamental Change if the holder had exchanged its note for ordinary shares immediately prior to the consummation of such Fundamental Change, plus any accrued and unpaid interest.
|
|
| Fair value of derivative liability |
|
|
|
|
$ 27,038,000
|
|
|
|
|
| Fair value of derivative liability related to rights offering |
|
|
|
|
82,000
|
|
|
|
|
| Financing transaction costs |
|
|
|
|
|
|
|
$ 2,815,000
|
|
| Financing transaction costs, capitalized |
|
|
|
|
|
|
2,814,000
|
2,814,000
|
|
| 2025 Exchangeable Notes | Subsequent Event |
|
|
|
|
|
|
|
|
|
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
| Debt instrument, shares embedded within each unit, shares | shares |
1,286.1845
|
1,000
|
|
|
|
|
|
|
|
| Debt instrument, shares embedded within each unit, value |
$ 1,000
|
$ 1,000
|
|
|
|
|
|
|
|
| Debt instrument, shares embedded within each unit, exchange price | $ / shares |
$ 0.7775
|
$ 1.00
|
|
|
|
|
|
|
|
| 2025 Exchangeable Notes | Private Placement |
|
|
|
|
|
|
|
|
|
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
|
$ 200,000
|
|
$ 51,600,000
|
|
|
|
|
| Debt instrument interest rate |
|
|
6.50%
|
|
6.50%
|
|
|
|
|
| Debt instrument price per unit |
|
|
$ 1,000
|
|
$ 1,000
|
|
|
|
|
| RLNs | Private Placement |
|
|
|
|
|
|
|
|
|
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
|
$ 20,000
|
|
$ 100,000
|
|
|
|
|
| Number of debt instruments within each notes | Debtinstrument |
|
|
50
|
|
50
|
|
|
|
|
| Securities | Private Placement |
|
|
|
|
|
|
|
|
|
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
| Debt instrument price per unit |
|
|
$ 1,000
|
|
$ 1,000
|
|
|
|
|
| Debt instrument, shares embedded within each unit, shares | shares |
|
|
1,000
|
|
1,000
|
|
|
|
|
| Debt instrument, shares embedded within each unit, value |
|
|
$ 1,000
|
|
$ 1,000
|
|
|
|
|
| Debt instrument, shares embedded within each unit, exchange price | $ / shares |
|
|
$ 1.00
|
|
$ 1.00
|
|
|
|
|
| Securities | Private Placement | Subsequent Event |
|
|
|
|
|
|
|
|
|
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
| Debt instrument, shares embedded within each unit, shares | shares |
1,286.1845
|
|
|
|
|
|
|
|
|
| Debt instrument, shares embedded within each unit, value |
$ 1,000
|
|
|
|
|
|
|
|
|
| Debt instrument, shares embedded within each unit, exchange price | $ / shares |
$ 0.7775
|
|
|
|
|
|
|
|
|
| Paycheck Protection Program |
|
|
|
|
|
|
|
|
|
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
| Interest expense |
|
|
|
|
|
|
$ 1,000
|
$ 3,000
|
|
| Paycheck Protection Program | Silicon Valley Bank (SVB) | Iterum Therapeutics US Limited |
|
|
|
|
|
|
|
|
|
| Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
| Aggregate principal amount |
|
|
|
$ 744,000
|
|
|
|
|
|
| Debt instrument interest rate |
|
|
|
1.00%
|
|
|
|
|
|
| Debt instrument maturity period |
|
|
|
2 years
|
|
|
|
|
|
| Minimum percentage of loan proceeds used for payroll costs |
|
|
|
60.00%
|
|
|
|
|
|
| Debt instrument, description |
|
|
|
Under the terms of the agreement, there shall be no payments due by the Company until the later of the date the SBA remits the forgiveness amount to the borrower or 10 months after the end of the six-month period beginning April 30, 2020 (the Deferral Period). Following the Deferral Period, equal monthly repayments of principal and interest will be due to fully amortize the principal amount outstanding on the PPP loan on the last day of the Deferral Period by the maturity date. Under the terms of the Program, the SBA will forgive the portion of loan proceeds used for U.S. payroll costs and other designated operating expenses for up to 24 weeks, provided at least 60% of the loan proceeds are used for U.S. payroll costs. The Company incurred qualifying payroll costs and other operating expenses in the 24 weeks following April 30, 2020, and has requested forgiveness for a portion of the PPP loan from the Lender
|
|
|
|
Under the terms of the agreement, there shall be no payments due by the Company until the later of the date the SBA remits the forgiveness amount to the borrower or 10 months after the end of the six-month period beginning April 30, 2020 (the Deferral Period). Following the Deferral Period, equal monthly repayments of principal and interest will be due to fully amortize the principal amount outstanding on the note on the last day of the Deferral Period by the maturity date. Under the terms of the Program, the SBA will forgive the portion of loan proceeds used for payroll costs and other designated operating expenses for up to 24 weeks, provided at least 60% of the loan proceeds are used for payroll costs. The Company incurred qualifying payroll costs and other operating expenses in the 24 weeks from April 30, 2020, and has requested forgiveness for a portion of the loan from the Lender
|
|